Dalaker K
Br J Obstet Gynaecol. 1986 Jan;93(1):17-21. doi: 10.1111/j.1471-0528.1986.tb07806.x.
During pregnancy the activity of coagulation factor VII in plasma increases up to 248% (SEM 16) (n = 18) at 40 weeks even when all precautions to avoid cold activation are taken. This increase is at all times during pregnancy, delivery and puerperium entirely due to the presence in vivo of what is most likely a phospholipid-factor VII complex. This complex is sensitive to phospholipase C, so that treatment with the enzyme reduces the activity of pregnant plasma down to that of non-pregnant controls. When present in the complex factor VII has a higher specific activity and an altered conformation with a more accessible active site as demonstrated by increased susceptibility to inactivation by diisopropylfluorophosphate. Factors II and X are increased to 136% (SEM 4) and 171% (SEM 6) (n = 18) without being sensitive to phospholipase C. The increase during pregnancy and the decrease after delivery of the phospholipase-sensitive factor VII activity have been followed.
在孕期，即使采取了所有避免冷激活的预防措施，血浆中凝血因子VII的活性在40周时仍可增加至248%（标准误16）（n = 18）。孕期、分娩期及产褥期的这种增加始终完全归因于体内最可能存在的磷脂 - 因子VII复合物。该复合物对磷脂酶C敏感，因此用该酶处理可使妊娠血浆活性降至非妊娠对照的水平。当因子VII存在于复合物中时，其比活性更高且构象改变，活性位点更易接近，这表现为对二异丙基氟磷酸失活的敏感性增加。因子II和X分别增加至136%（标准误4）和171%（标准误6）（n = 18），且对磷脂酶C不敏感。已对磷脂酶敏感的因子VII活性在孕期的增加及产后的降低情况进行了跟踪研究。
